Project Grant R01CA289772

Award Date 5/10/24
Completion Date 4/30/29
Dollars Obligated $1.8M
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Kansas City, KS 66160, USA
Similar Awards
This federal Project Grant award, with the ID K08CA285952, is funded by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program. The $197,640 award supports an initiative led by Dr. Adjoa Anyane-Yeboa at the Massachusetts General Hospital (MGH) to develop implementation strategies for increasing colorectal cancer (CRC) screening rates among unscreened individuals aged 45-54, with a focus on racial/ethnic minority populations. The key objectives of this 5-year...
This Project Grant award of $622,913 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports research to evaluate a multilevel intervention to increase colonoscopic follow-up after abnormal stool-based colorectal cancer screening in a federally qualified health center (FQHC) setting. The primary objective is to compare the effectiveness of the multilevel intervention versus usual care on receipt of colonoscopy within 6 months of an...
This Project Grant award from the National Cancer Institute (NCI) under CFDA Program 93.398 (Cancer Research Manpower) will fund a research project to pilot an implementation strategy for increasing the use of mainstream genetic testing (MGT) for colorectal cancer (CRC) patients. The $192,433 award will support a 5-year project focused on characterizing barriers to implementing MGT and piloting a multi-level implementation strategy tailored to these barriers. Key activities include assessing...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $696,852 to Harvard T.H. Chan School of Public Health to optimize a mobile messaging intervention for increasing colorectal cancer (CRC) screening rates among patients served by community health centers (CHCs). The project aims to first focus on maximizing patient engagement by determining optimal messaging strategies for a text message-based...
This $946,500 Cooperative Agreement award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) aims to test the effectiveness of strategies to promote high-quality, evidence-based cancer survivorship care in rural primary care practices in Kansas. The project, titled "KANSURVIVE 2.0", will implement a three-arm cluster-randomized, multi-level intervention to provide...
This $269,942 Project Grant from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports the development and pilot testing of a four-part community health worker (CHW) intervention to improve lung cancer screening uptake and address disparities among Black and Hispanic populations. The key products or services to be delivered under this 5-year award include: 1) jointly "transcreating" the CHW intervention with a community advisory board, 2) conducting...
This federal Project Grant award of $591,691 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will fund a pragmatic randomized controlled trial to evaluate an intervention called "Current Together After Cancer" (CTAC) for promoting guideline-concordant colorectal cancer surveillance among stage II and III colorectal cancer survivors. The key objectives are to (1) determine the effect of CTAC on improving survivors' knowledge about and...
The federal Project Grant award R01CA282292 for $663,428, provided by the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research to address cancer risk factors and prevention strategies in primary care settings. The project aims to evaluate the comparative effectiveness of two implementation strategy bundles to deliver a web-based intervention called "My Own Health Report" (MOHR) that screens for multiple cancer risks, sets...
This $637,596 Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research program) will fund a research project to test a video-based intervention strategy for reducing defensive colorectal cancer information avoidance and increasing screening uptake. The project aims to reach individuals who tend to avoid colorectal cancer information, as they are less likely to adhere to screening guidelines. The research plan includes a randomized controlled...
This Project Grant award, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Kansas Medical Center Research Institute, Inc., aims to establish and refine processes that facilitate clinical trials in cancer interception (active cancer prevention) at the University of Kansas Cancer Center. The $172,197 award, effective September 1, 2024 through August 31, 2029, will fund initiatives to: hire project navigators to facilitate study approvals,...

PB-ICRC: MULTI-SITE PRACTICE-BASED IMPLEMENTATION OF A COLORECTAL CANCER SCREENING INTERVENTION - PROJECT SUMMARY/ABSTRACT ALTHOUGH "IMPLEMENTATION INTENTIONS"-BASED TOOLS HAVE BEEN FOUND TO ENHANCE COLORECTAL CANCER (CRC) SCREENING UPTAKE, PRIOR STUDIES HAVE NOT TESTED TO SCALE THEIR IMPLEMENTATION INTO ROUTINE PRIMARY CARE DELIVERY SETTINGS SERVING HARD-TO-REACH POPULATIONS SUCH AS THOSE WITH LIMITED ENGLISH PROFICIENCY. OUR RESEARCH GROUP, LED BY PROF. KA GREINER, HAS DEVELOPED AND TESTED AN "I2" CRC DECISION-MAKING TOOL VIA MULTIPLE NCI-FUNDED STUDIES. IT ADDRESSES THE "WHEN," "WHERE" AND "HOW" DETAILS OF SCREENING VIA STOOL SAMPLE TESTS OR COLONOSCOPY. IN THIS STUDY, WE WILL CONDUCT A PARALLEL CLUSTER-RANDOMIZED TRIAL IN 20 CLINICS PARTICIPATING IN THE AMERICAN ACADEMY OF FAMILY PHYSICIANS NATIONAL RESEARCH NETWORK, SERVING COMMUNITIES IN WHICH AT LEAST 25% OF THE PATIENT POPULATION'S PREFERRED LANGUAGE IS SPANISH. SPECIFIC AIMS FOR THE PROJECT WILL BE: (AIM 1) TO COMPARE CRC SCREENING OUTCOMES AT 6 MONTHS BETWEEN TWO IMPLEMENTATION APPROACHES FOR OUR "I2 TOOL" : (1) IMPLEMENTATION THROUGH A NORMALIZATION PROCESS THEORY-GUIDED PARTICIPATORY LEARNING IN ACTION (NPT-PLA ARM) PROCESS VERSUS (2) IMPLEMENTATION WITH A USUAL QUALITY IMPROVEMENT PROCESS (CONTROL ARM) IN PRIMARY CARE PRACTICES USING A PARALLEL CLUSTER RANDOMIZED TRIAL; AND (AIM 2) TO EVALUATE THE FACILITATORS AND BARRIERS OF THE IMPLEMENTATION APPROACH IN EACH STUDY ARM USING THE NORMALIZATION PROCESS THEORY (NPT) FRAMEWORK. MULTI-DISCIPLINARY CLINIC `IMPLEMENTATION TEAMS' THAT INCLUDE CLINIC STAFF AND PATIENTS WHOSE PREFERRED LANGUAGE IS SPANISH WILL MEET MONTHLY DURING THE FIRST 6 MONTHS OF CLINIC PARTICIPATION AND AIM TO INTEGRATE THE I2 TOOL INTO ROUTINE PRIMARY CARE DELIVERY, USING THE NPT-PLA INTERVENTION OR CONTROL APPROACH. THE I2 TOOL WILL BE DELIVERED VIA AN ON-LINE REDCAP SURVEY OR (IF PATIENTS PREFER) BY PAPER FORM; AND HAS BEEN CUSTOMIZED FOR USE IN ENGLISH AND SPANISH. WE WILL ENROLL ALL PATIENTS IN EACH CLINIC ELIGIBLE FOR CRC SCREENING (A MINIMUM OF 100 PER CLINIC). PRIMARY (AIM 1) OUTCOMES WILL BE CRC SCREENING ORDERS PLACED (BY CLINIC STAFF) AND COMPLETION OF CRC SCREENING (BY PATIENTS) OVER 6 MONTHS OF PATIENT FOLLOW-UP AFTER INITIAL EXPOSURE TO THE I2 TOOL. A SECONDARY AIM WILL BE TO DETERMINE WHETHER COMPLETION OF THE I2 SCREENING TOOL VARIES BETWEEN STUDY ARMS. FOR AIM 2, IN ALL CLINICS AT BASELINE AND AFTER 6 MONTHS OF CLINIC PARTICIPATION WE WILL ADMINISTER A SURVEY BASED ON THE NPT CONSTRUCTS (THE "NOMAD") TO ASSESS IMPLEMENTATION TEAM MEMBERS' COMPREHENSION OF THEIR ROLE IN THE PROJECT, THE SALIENCE OF OUR INTERVENTION APPROACH, THEIR BUY-IN, THE FEASIBILITY OF ALTERING WORKFLOWS, AND THE POTENTIAL SUSTAINABILITY OF THE INTERVENTION IN THEIR CLINICAL SETTING. WE WILL ALSO CONDUCT SUMMATIVE QUALITATIVE FOCUS GROUP DISCUSSIONS IN ALL CLINICS WITH THE IMPLEMENTATION TEAM AFTER 6 MONTHS OF CLINIC PARTICIPATION, AND AT 12 MONTHS WITH TEAM LEADERS TO ASSESS MAINTENANCE. KEY PERSONNEL INCLUDE THE MULTIPLE-PIS (KA GREINER, J LEMASTER, C HESTER), KUMC BIOSTATISTICIAN B GAJEWSKI AND AN INTERNATIONAL NPT EXPERT, A MACFARLANE. THE STUDY WILL PROVIDE IMPORTANT INFORMATION ON BARRIERS AND FACILITATORS OF EMBEDDING NPT-PLA INTERVENTIONS IN "REAL-WORLD" PRIMARY CARE CLINICAL SETTINGS TO PROMOTE CANCER SCREENING SUCCESSFULLY.

Posted 5/10/24, 12:00 AM